Leap Therapeutics Reports Second Quarter 2025 Financial Results
Selected Second Quarter 2025 Financial Results Net Loss was 20.4 million for the second quarter 2024. The decrease was primarily due to a decrease in research and development and general and administrative expenses, offset in part by a restructuring charge associated with the reduction in force. Research and development expenses were 17.9 million for the same period in 2024. The decrease of $7. ...